Mandate

Vinge has advised GeneraLife in connection with its acquisition of Livio Group

Vinge has advised GeneraLife, one of Europe's largest fertility clinic groups and owned by KKR, in connection with its acquisition of Livio Group.

Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway and Iceland. The acquisition also encompasses the Livio's own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark.

Vinge's team consisted of responsible partner Matthias Pannier and associates, Samra Baytar, Stina Bengtsson, Olivia Belding, Elias Bohlin (M&A), Trine Osen Bergqvist, Johan Wahlbom, Jakob Jeanrond, Victoria Fredén, Alva Chambert (Antitrust), Christoffer Nordin, Mika Jordan (Regulatory & Agreements), Rebecka Målquist (IP), Frida Ställborn, Karolina Cohrs (Real Estate), Calle Tengwall Pagels (Banking & Finance), Gustav Lindgren (Employment), Karolina Fuhrman (IT & GDPR) and Jessica Henning (Project Assistance).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026